TY - JOUR
T1 - Progress toward the clinical application of patient-specific pluripotent stem cells
AU - Kiskinis, Evangelos
AU - Eggan, Kevin
PY - 2010/1/4
Y1 - 2010/1/4
N2 - Induced pluripotent stem (iPS) cells are generated by epigenetic reprogramming of somatic cells through the exogenous expression of transcription factors. These cells, just like embryonic stem cells, are likely to have a major impact on regenerative medicine, because they self-renew and retain the potential to be differentiated into all cell types of the human body. In this Review, we describe the current state of iPS cell technology, including approaches by which they are generated and what is known about their biology, and discuss the potential applications of these cells for disease modeling, drug discovery, and, eventually, cell replacement therapy.
AB - Induced pluripotent stem (iPS) cells are generated by epigenetic reprogramming of somatic cells through the exogenous expression of transcription factors. These cells, just like embryonic stem cells, are likely to have a major impact on regenerative medicine, because they self-renew and retain the potential to be differentiated into all cell types of the human body. In this Review, we describe the current state of iPS cell technology, including approaches by which they are generated and what is known about their biology, and discuss the potential applications of these cells for disease modeling, drug discovery, and, eventually, cell replacement therapy.
UR - http://www.scopus.com/inward/record.url?scp=74949133926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949133926&partnerID=8YFLogxK
U2 - 10.1172/JCI40553
DO - 10.1172/JCI40553
M3 - Review article
C2 - 20051636
AN - SCOPUS:74949133926
SN - 0021-9738
VL - 120
SP - 51
EP - 59
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 1
ER -